One Inmate’s Fatal Struggle Highlights Systemic Failures (Image Credits: Mirrorball.themarshallproject.org)
Missouri – A civil rights lawsuit filed this week targets the state Department of Corrections and its healthcare contractor for systematically denying medication-assisted treatment to inmates with opioid use disorder, exacerbating risks in a drug-permeated prison system.[1]
One Inmate’s Fatal Struggle Highlights Systemic Failures
Bradley Ketcherside’s repeated pleas for medication fell on deaf ears before his overdose death in January 2025 at Crossroads Correctional Center.[1] He sought medically assisted treatment multiple times, only to face rejections tied to his distant release date, solitary confinement status, or insufficient signs of addiction during a brief evaluation.
Evaluators dismissed his desperation – even after he warned that medication “would save my life” – because he had shifted to synthetic cannabinoids like K2 following an earlier overdose.[1] Six days later, staff discovered him unresponsive in his cell. Despite Narcan administration, he could not be revived. His widow now leads the suit, alleging deliberate indifference to serious medical needs.
Arbitrary Barriers Block Access to Proven Care
The lawsuit details a pattern of denials based on criteria such as recent overdose history, sentence length, or sobriety duration, leaving nearly 7,000 diagnosed inmates vulnerable last year.[1] Inmates reported providers citing non-withdrawal states or insisting on waiting for another overdose before approving aid.
Punishments compound the crisis: positive drug tests trigger solitary confinement, wage deductions, or delayed releases, even as contraband floods facilities.[1] One inmate endured forced naltrexone, which blocks opioid effects but fails to curb cravings effectively, unlike gold-standard options buprenorphine and methadone.
- Overdose deemed not “recent enough.”
- Sentence too long for eligibility.
- Solitary confinement disqualifies applicants.
- Shift to other drugs like K2 voids claims.
- Preference for less effective naltrexone over craving-stemmers.
Drugs Thrive Despite Security Gaps
Missouri prisons brim with opioids and synthetics, smuggled by staff, drones, or unsecured entrances, yet officials prioritize inmate blame over robust prevention.[1] Employees faced charges for trafficking, including a case yielding an 87-month sentence, while facilities like Crossroads operated without overnight entry guards for months.
Overdoses persist: 46 struck state prisons in September 2022 alone, with recent fatalities underscoring untreated addiction’s toll.[2][1] Similar denials claimed Brandon Church, who lost MAT in solitary and died by suicide weeks later after begging for help.
Treatment Expansion Lags Behind Need
The DOC plans to grow MAT recipients from 121 in 2024 to 841 by summer 2026, backed by nearly $7 million in opioid settlement funds, yet current reach covers only a fraction of cases.[1] Costs range from $6,500 to $14,200 per person annually, straining budgets amid rising diagnoses from improved screening.
| Medication | Mechanism | Prison Use |
|---|---|---|
| Buprenorphine | Binds receptors, reduces cravings | Limited by policy barriers |
| Methadone | Binds receptors, stems withdrawal | Rarely prioritized |
| Naltrexone | Blocks opioid effects | Common, despite lower efficacy |
Experts criticize private provider Centurion for profit-driven restrictions, while the DOC insists counseling and tiered programs suffice.[1] Lead attorney Leah Fessler decried the “huge injustice,” with stakes of life and death.
Key Takeaways:
- Nearly 7,000 inmates diagnosed with opioid use disorder in 2025, but treatment reaches few.
- Staff smuggling and policy gaps fuel contraband influx.
- Lawsuit seeks reforms, damages, and punitive measures for accountability.
As Missouri prisons confront this deadly shortfall, advocates push for evidence-based care over punishment. Reforms could save lives and curb recidivism – what steps should the DOC take next? Share your thoughts in the comments.
